Clinical Trials for Pancreas Cancer

A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic or unresectable gastrointestinal cancers (including mCRC, gastric/GEJ, pancreatic, cholangiocarcinoma) eligible for FOLFOX, generally after at least one prior line; current randomized expansion focuses on second-line mCRC that is oxaliplatin-naïve, BRAF WT, MSI-stable, and not receiving biologics. Investigational agent BOLD-100, a ruthenium-based compound that inhibits GRP78/BiP to disrupt ER stress and induce apoptosis, is combined with standard FOLFOX.

ClinicalTrials.gov ID: NCT04421820

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced/metastatic solid tumors, including biomarker-selected cohorts (e.g., ATM loss/alterations; platinum‑resistant high‑grade serous ovarian cancer; selected endometrial, colorectal, and pancreatic cancers), after appropriate standard therapies. Investigational therapy is ART0380, an oral ATR kinase inhibitor exploiting replication-stress/synthetic lethality, given as monotherapy or combined with gemcitabine or irinotecan; includes a randomized cohort of platinum‑resistant ovarian cancer comparing ART0380+gemcitabine versus gemcitabine.

ClinicalTrials.gov ID: NCT04657068

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic GI adenocarcinomas (colorectal, pancreaticobiliary, or upper GI) progressing after standard therapy receive sacituzumab govitecan (Trop-2–targeted ADC delivering SN-38/topoisomerase I inhibitor) plus capecitabine in 21-day cycles; prior topo I inhibitor exposure is excluded, treated/stable brain mets allowed. Dose-escalation assesses safety/tolerability and seeks an RP2D, with exploratory correlation to tumor Trop-2 expression.

ClinicalTrials.gov ID: NCT06065371

ParpVax2: A Phase II Study Of Maintenance Niraparib Plus Ipilimumab In Patients With Metastatic Pancreatic Cancer Whose Disease Has Not Progressed On Platinum-Based Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma with at least stable disease after 8–12 cycles of platinum-based induction (FOLFIRINOX or NALIRIFOX; ECOG 0–1) are randomized to maintenance niraparib (PARP-1/2 inhibitor) plus ipilimumab (CTLA-4 inhibitor) versus continued chemotherapy (FOLFIRI). Key exclusions include prior PARP/CTLA-4 therapy, known pathogenic BRCA1/2/PALB2/RAD51C/D alterations, and dMMR/MSI-H disease.

ClinicalTrials.gov ID: NCT06747845

A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with untreated, biopsy-proven metastatic pancreatic adenocarcinoma (ECOG 0–1) receive first-line gemcitabine plus nab-paclitaxel combined with the TheraBionic device, which delivers low-intensity, amplitude‑modulated radiofrequency electromagnetic fields intended to modulate tumor cell signaling and calcium channel activity. Key exclusions include prior systemic therapy for metastatic disease, recent adjuvant/neoadjuvant gemcitabine or nab-paclitaxel, brain metastases, significant cardiopulmonary disease, and concurrent use of L-/T-type calcium channel blockers unless discontinued.

ClinicalTrials.gov ID: NCT05776524

Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic pancreatic adenocarcinoma (ECOG 0–1) receive standard gemcitabine plus nab-paclitaxel combined with the TheraBionic P1 device delivering amplitude-modulated radiofrequency electromagnetic fields, a noninvasive biophysical modality hypothesized to disrupt tumor signaling and proliferation. Excludes recent gemcitabine/nab-paclitaxel in the adjuvant/neoadjuvant setting, brain metastases, and patients on L- or T-type calcium channel blockers unless discontinued.

ClinicalTrials.gov ID: NCT06576115

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with measurable, unresectable/metastatic tumors harboring KRAS/NRAS/HRAS mutations or non–BRAF V600E MAPK-pathway alterations (with dedicated cohorts for MEK-naive LGSOC, MEK-pretreated LGSOC, pancreatic cancer post ≥1 line, and other solid tumors per ComboMATCH) receive palbociclib (CDK4/6 inhibitor) plus binimetinib (MEK1/2 inhibitor), with a randomized comparison to binimetinib alone in MEK-naive LGSOC. Key exclusions include RB1 loss and BRAF V600E; crossover to combination is allowed at progression in the LGSOC randomized cohort.

ClinicalTrials.gov ID: NCT05554367

Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with metastatic or unresectable solid tumors, including expansion cohorts for squamous NSCLC, pancreatic cancer, head and neck SCC (non-oropharynx or HPV− oropharynx), or tumors with PI3K-pathway alterations (e.g., PIK3CA mutation/amplification or PTEN loss). Patients receive oral palbociclib (CDK4/6 inhibitor) D1–21 q28d plus weekly IV gedatolisib, a pan–class I PI3K and dual mTORC1/2 inhibitor.

ClinicalTrials.gov ID: NCT03065062

A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with well-differentiated, unresectable or metastatic GI, lung, or pancreatic NETs (functional or non-functional) with measurable disease, ECOG 0–1, and ≤2 prior systemic lines (excluding SSAs), but no prior mTOR inhibitors, receive nab-sirolimus monotherapy. Nab-sirolimus is an albumin-bound sirolimus (mTORC1 inhibitor) formulation designed to enhance tumor delivery; functional NETs must be on a stable SSA dose with documented progression.

ClinicalTrials.gov ID: NCT05997056

Phase 2 Trial of Ablative MRI-guided Stereotactic Body Radiation Therapy and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with unresectable, nonmetastatic locally advanced pancreatic adenocarcinoma who have completed ≥3 months of induction FOLFIRINOX or gemcitabine/nab-paclitaxel (without distant progression) receive consolidative MRI-guided ablative SBRT (50 Gy/5 fx) plus concurrent Tumor Treating Fields (NovoTTF-100L), a device delivering alternating electric fields that disrupt mitosis, continued until progression or intolerance. Key criteria include ECOG 0–1, CA 19-9 ≤500 U/mL, no prior abdominal RT, and no MRI or torso-implantable device contraindications.

ClinicalTrials.gov ID: NCT05679674